Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

Autoinflammatory Diseases: Clinical and Genetic Advances

(2010) S. Farasat et al.   ARCHIVES OF DERMATOLOGY

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes

(2009) Helen J. Lachmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus

(2008) L C Doward et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies

(2008) Hal M. Hoffman et al.   ARTHRITIS AND RHEUMATISM

Autoinflammatory diseases

(2008) Isabelle Touitou et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

The spectrum of monogenic autoinflammatory syndromes: Understanding disease mechanisms and use of targeted therapies

(2008) Rachel L. Glaser et al.   CURRENT ALLERGY AND ASTHMA REPORTS

The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

(2008) Rieke Alten et al.   ARTHRITIS RESEARCH & THERAPY